TF
Terence Flynn Morgan Stanley Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
|
ALMS
1
Alumis Inc. Common Stock
ALMS
$469M
| $4.51 | $22 |
388%
upside
| Overweight | 23 days ago |
|
2
Biohaven
BHVN
$1.68B
| $15.87 | $54 |
240%
upside
| Overweight | 26 days ago |
|
3
Pfizer
PFE
$141B
| $24.88 | $33 |
33%
upside
| Equal-Weight | 1 month ago |
|
4
Amgen
AMGN
$153B
| $283.64 | $333 |
17%
upside
| Equal-Weight | 1 month ago |
|
5
AbbVie
ABBV
$375B
| $212.56 | $255 |
20%
upside
| Overweight | 1 month ago |
|
6
Johnson & Johnson
JNJ
$430B
| $178.43 | $176 |
1%
downside
| Equal-Weight | 1 month ago |
|
7
Nurix Therapeutics
NRIX
$758M
| $9.91 | $16 |
61%
upside
| Equal-Weight | 1 month ago |
|
8
Royalty Pharma
RPRX
$15.6B
| $36.07 | $54 |
50%
upside
| Overweight | 1 month ago |
|
9
Merck
MRK
$212B
| $84.71 | $98 |
16%
upside
| Equal-Weight | 1 month ago |
|
10
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $34 |
28%
downside
| Underweight | 1 month ago |
|
11
BioNTech
BNTX
$27B
| $112.46 | $133 |
18%
upside
| Overweight | 1 month ago |
|
12
Eli Lilly
LLY
$652B
| $727.21 | $1,135 |
56%
upside
| Overweight | 1 month ago |
|
13
United Therapeutics
UTHR
$18.1B
| $400.52 | $328 |
18%
downside
| Equal-Weight | 1 month ago |
|
14
Arvinas
ARVN
$575M
| $7.83 | $11 |
40%
upside
| Equal-Weight | 4 months ago |
|
15
Arcus Biosciences
RCUS
$1.3B
| $12.19 | $22 |
80%
upside
| Overweight | 4 months ago |
|
16
Organon & Co
OGN
$2.7B
| $10.38 | $10 |
4%
downside
| Equal-Weight | 4 months ago |
|
17
CRISPR Therapeutics
CRSP
$4.99B
| $54.86 | $32 |
42%
downside
| Underweight | 6 months ago |
|
18
Intellia Therapeutics
NTLA
$1.29B
| $12.06 | $11 |
9%
downside
| Equal-Weight | 7 months ago |
|
19
Structure Therapeutics
GPCR
$1.27B
| $22.08 | $118 |
434%
upside
| Overweight | 11 months ago |
|
20
Biogen
BIIB
$20.6B
| $140.67 | $436 |
210%
upside
| Neutral | 4 years ago |
|
|
21
Eli Lilly
LLY
$652B
| $727.21 | $270 |
63%
downside
| Buy | 4 years ago |
|
|
22
Pfizer
PFE
$141B
| $24.88 | $40 |
61%
upside
| Neutral | 4 years ago |
|
|
23
Merck
MRK
$212B
| $84.71 | $105 |
24%
upside
| Buy | 5 years ago |
|